Sagie Haziza

Sagie Haziza

Auto-generated profile, based on publicly available information

Sagie Haziza

Department of Orthopedic Surgery, Rutgers New Jersey Medical School, University Hospital, Newark, NJ 07103, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in JBJS Case Connector
Verified
Journal Article
Closed access
DMDustin H. Massel
Dustin H. Massel
SHSagie Haziza
Sagie Haziza
SRSebastian Rivera
Sebastian Rivera
NMNeil Mohile
Neil Mohile
TSTy Subhawong
Ty Subhawong
VHVictor H. Hernandez
Victor H. Hernandez
Case: We report a case of a 68-year-old woman who developed left shoulder glenohumeral joint septic arthritis within 1 week of receiving the COVID-19 Pfizer-BioNTech vaccine. Conclusion: Common vaccine complications include injection site pain, fever, chills, arthralgia, and hypersensitivity reactions. A less common and more serious complication of septic arthritis has been reported and requires invasive treatment of surgical irrigation and debridement, and culture-specific parenteral antibiotic therapy. The current report highlights the clinical presentation and significant potential for serious complication with the improper technique. We urge vaccine administrators to practice caution and aseptic technique when vaccinating patients to reduce the risk of complication and morbidity.

19 January 2022 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
DCDavid S. Constantinescu
David S. Constantinescu
SHSagie Haziza
Sagie Haziza
DBDennis J. Vanden Berge
Dennis J. Vanden Berge
CMColin A. McNamara
Colin A. McNamara
VHVictor H. Hernandez
Victor H. Hernandez
MDMichele R. D’aPuzzo
Michele R. D’aPuzzo

2 December 2021 in Archives of orthopaedic and trauma surgery
Verified
Journal Article
Closed access
PDF file
RYRamakanth R. Yakkanti
Ramakanth R. Yakkanti
NMNeil V. Mohile
Neil V. Mohile
WCWayne B. Cohen-Levy
Wayne B. Cohen-Levy
SHSagie Haziza
Sagie Haziza
MLMatthew J. Lavelle
Matthew J. Lavelle
SQStephen M. Quinnan
Stephen M. Quinnan

1 August 2021 in The Knee
Verified
Journal Article
Closed access
SSSpencer Summers
Spencer Summers
RYRamakanth Yakkanti
Ramakanth Yakkanti
SHSagie Haziza
Sagie Haziza
RVRushabh Vakharia
Rushabh Vakharia
MRMartin W. Roche
Martin W. Roche
VHVictor H. Hernandez
Victor H. Hernandez

31 August 2021 in The Journal of Knee Surgery
Verified
Journal Article
Closed access
PDF file
SSSpencer Summers
Spencer Summers
RYRamakanth Yakkanti
Ramakanth Yakkanti
JOJustin Ocksrider
Justin Ocksrider
SHSagie Haziza
Sagie Haziza
AMAngelo Mannino
Angelo Mannino
VHVictor H. Hernandez
Victor H. Hernandez
Chronic venous insufficiency (CVI) is extraordinarily prevalent in our aging population with over 30 million people in the United States suffering from the disease. There is a paucity of data analyzing the effects of CVI on outcomes following total knee arthroplasty (TKA). The purpose of this study was to utilize a nationwide administrative claims database to determine whether patients with CVI undergoing TKA have higher rates of: (1) in-hospital lengths of stay (LOS); (2) readmission rates; (3) medical complications; (4) implant-related complications; and (5) costs of care compared to controls. Using a nationwide database, we matched patients with CVI undergoing TKA to controls without CVI undergoing TKA in a 1:5 ratio by age, sex, and medical comorbidities associated with CVI. Primary outcomes analyzed within the study included LOS, 90-day readmission rates, 90-day medical complications, 2-year implant-related complications, in addition to 90-day total global episode of care costs. The query yielded 1,265,534 patients with (n = 210,926) and without (n = 1,054,608) CVI undergoing primary TKA. Patients with CVI had significantly longer LOS (4 vs. 3 days, p < 0.0001), higher 90-day readmission rates (20.96 vs. 15.34%; odds ratio [OR]: 1.46, 95% confidence interval [CI]: 1.44–1.48, p < 0.0001), and higher odds of medical complications (2.27 vs. 1.30%; OR: 1.76, 95% CI: 1.70–1.83, p < 0.0001) compared to matched controls. Patients with CVI also had higher odds of periprosthetic joint infections (2.23 vs. 1.03%; OR: 2.18, p < 0.0001) and implant-related complications in general (4.27 vs. 2.17%; OR: 2.01, 95% CI: 1.96–2.06, p < 0.0001). Additionally, patients with CVI had higher total global 90-day episode of care costs ($15,583.07 vs. $14,286.95, p < 0.0001). Patients with CVI undergoing TKA have increased LOS, higher odds of medical and implant complications, and increased costs of care compared to those without CVI. The study can be utilized by orthopaedic surgeons to counsel patients on the potential complications following this procedure. This is a level III, retrospective cohort study.

1 April 2022 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
GRGireesh B. Reddy
Gireesh B. Reddy
SHSagie Haziza
Sagie Haziza
DCDavid S. Constantinescu
David S. Constantinescu
DPDianne N. Pagan
Dianne N. Pagan
MSMichaela M. Schneiderbauer
Michaela M. Schneiderbauer
VHVictor H. Hernandez
Victor H. Hernandez